Evaluation of a New Oral Contrast Agent for MR Enterography in the Assessment of Crohn Disease in the Small Bowel



Status:Completed
Conditions:Gastrointestinal, Crohns Disease
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:June 2004
End Date:December 2008

Use our guide to learn which trials are right for you!

The purpose of this study is to assess the exam quality and accuracy of MR using a new oral
contrast agent for the evaluation of Crohn Disease in the small bowel.

Crohn Disease is an inflammatory condition that involves the small bowel. Patients usually
undergo multiple imaging exams in the diagnosis and surveillance of the disease. CT has been
shown to have excellent results for detecting active inflammation. In the United States MR
has lagged behind CT in utilization for imaging the small bowel. An advantage of MR over CT
is the lack of radiation exposure to the patient. A new oral contrast agent is available
that provides good distension of the small bowel and allows improved identification of
active inflammation. The purpose of this study is to compare the accuracy of MR to CT using
this new oral contrast agent and to assess exam quality.

Inclusion Criteria:

- Known or suspected Crohn Disease

- Undergoing colonoscopy and CT enterography

Exclusion Criteria:

- Contraindication to MR
We found this trial at
1
site
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials